Biotech Co.* (Country; Symbol)

Pharma Co. (Country)


Terms/Details (Date)

Advancis Pharmaceutical Corp. (AVNC)

Ceph International Inc.

Long-term supply agreement for Advancis' Keflex, a cephalosporin antibiotic

Advancis acquired the product from Eli Lilly and Co.; Ceph, a subsidiary of MOVA Pharmaceutical Corp., will supply product under undisclosed terms (12/9)

Aureus Pharma* (France)

Infocom Corp. (Japan)

Infocom will exclusively distribute Aureus products in Japan

The products are applicable to drug discovery; terms of the deal were not disclosed (12/10)

Avidia Research Institute

Boehringer Ingelheim Austria GmbH

BI will develop manufacturing technology for Avidia's Maxybody proteins

BI also will supply Maxybody proteins for use in clinical studies and commercial sale; terms were not disclosed (11/29)

Barrier Therapeutics Inc. (BTRX)

Grupo Ferrer Internacional SA (Spain)

Ferrer will exclusively market Barrier's Zimycan, Sebazole, Liarozole and Ketanserin in several countries in Europe, Latin America and Africa

Barrier's primary revenues will be from the sale of finished product to Ferrer; it also could earn milestone and royalty payments; Ferrer is responsible for getting approvals in the covered countries (11/4)

Cambridge Biostability Ltd.* (UK)

Panacea Biotec Ltd. (India)

Deal for the manufacture and sale of a pentavalent vaccine that uses CBL technology

The deal involves CBL's temperature-stable liquid formulation technology; Panacea will make and develop vaccine for developing countries in exchange for royalty payments (10/20)**

Cell Therapeutics Inc. (CTCI)

Five unnamed distributors

The companies will distribute Trisenox in Latin America, Eastern Europe, Israel, Turkey and South Africa

Terms of the deals were not disclosed (12/8)

CollaGenex Pharmaceuticals Inc. (CGPI)

Alliance Pharma plc (UK)

Alliance acquired the European assets of Colla-Genex's dental operations

Alliance paid $3.3M for the assets, which relate primarily to the product Periostat (10/22)

CV Therapeutics Inc. (CVTX)

Solvay Pharmaceuticals Inc.

Deal through 2010 for the co-promotion in the U.S. of Aceon, an angiotensin-converting enzyme inhibitor

CV Therapeutics will establish a cardiology-focused sales force for the product, and will receive royalties after sales exceed a certain baseline; Solvay will continue to manufacture and distribute the drug (12/6)

Depomed Inc. (DEPO)

LG Life Sciences Ltd. (South Korea)

Deal under which LG Life will sell Metformin GR in Korea

The product is an extended-release formulation of metformin for treating Type II diabetes; terms were not disclosed (11/9)

Dharmacon Inc.*

GE Healthcare

Distribution agreement for Dharmacon's RNAi research products in Japan

GE will exclusively distribute the products in Japan; terms were not disclosed (11/22)

Dynal Biotech ASA* (Norway)

Tecan Group AG (Switzerland)

Deal to to co-develop and market optimized robotic applications

They will use Dynal research kits on Tecan's Freedom EVO automated platform; terms were not disclosed (11/5)

ID Biomedical Corp. (Canada; IDBE)

Henry Schein Inc., Amerisource-Bergen Corp. and McKesson Corp.

Long-term marketing and minimum-purchase deals for sales of ID's Fluviral vaccine in the U.S.

Agreements with the three companies begin upon FDA approval of the influenza vaccine, and end in 2015; ID estimated purchases would total $2.3B over the life of the deals (12/6)

Inhibitex Inc. (INHX)

Lonza Group Ltd. (Switzerland)

Deal for the manufacturing of Inhibitex's anti-infective monoclonal antibody Aurexis

Lonza will manufacture Aurexis for future clinical trials using its glutamine synthetase expression system; terms were not disclosed (11/12)

Insmed Inc. (INSM)

Tzamal Pharma (Israel)

Tzamal gains exclusive rights to SomatoKine in certain Middle Eastern territories, including Israel

Tzamal also can expand Insmed's named-patient program for the IGF-I replacement therapy in those territories; terms of the deal were not disclosed (10/21)

Lorus Therapeutics Inc. (Canada; TSE:LOR)

Diagnostic Chemicals Ltd.

Deal for the commercial manufacture of Lorus' Phase III cancer product Virulizin

The deal was made with DCL operating as BioVectra dcl, which has a facility on Prince Edward Island; terms were not disclosed (11/16)

Martek Biosciences Corp. (MATK)

Beckman Coulter Inc.

Martek will supply its PBXL-1 protein-detection dye to Beckman Coulter

Terms of the nonexclusive, 10-year supply deal were not disclosed (11/4)

Molecular Diagnostics Inc. (OTC BB: MCDG)

Undisclosed biotech unit of a pharmaceutical company

Five-year deal for the manufacture and distribution of MDI's Automated Image Proteomic System

The initial contract is worth more than $600,000; they also will collaborate to develop antibodies to be used in the MDI proteomic cell-based assay systems (11/1)

Morphotek Inc.*

SC BioSciences (Japan)

SCB will market Morphotek's cell line-optimization services in Japan

Morphotek's Morphodoma technology is included in the deal, terms of which were not disclosed (11/15)

NascaCell IP GmbH* (Germany)

GE Healthcare Amersham Biosciences KK (Japan)

GE got exclusive rights to distribute NascaCell's aptamers in Japan

The aptamers will be used in target validation and drug discovery; terms were not disclosed (10/25)

NeuTec Pharma plc* (UK; AIM:NTP)

CMC Biopharmaceuticals (Denmark)

Deal under which CMC will provide manufacturing and other services for NeuTec's Mycograb

The product for candidiasis is in Phase III trials; terms of the deal were not disclosed (11/29)

Procognia Ltd.* (UK)

Sigma-Aldrich Corp.

Sigma-Aldrich will market arrays of functional human proteins developed by Procognia

The first array will contain wild-type human p53 and its germline SNP variants; terms of the deal were not disclosed (11/8)

The Genetics Co.* (Switzerland)

Funakoshi Co. Ltd. (Japan)

Funakoshi will distribute certain products from The Genetics Co. in Japan

The exclusive deal covers Alzheimer's disease diagnostics and research tools; terms were not disclosed (11/9)

VioQuest Pharmaceuticals Inc. (OTC BB:VQPH)

Selectchemie AG (Switzerland)

Selectchemie will distribute VioQuest catalysts and ligands in Eastern Europe

The deal with VioQuest subsidiary Chiral Quest Inc. also includes certain chemical companies in Western Europe (11/8)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments